RECOMBINANT BCG CANDIDATE VACCINE IMMUNOGENICITY STUDY

重组卡介苗候选疫苗免疫原性研究

• 批准号: 8358015
• 负责人: NORMAN L LETVIN
• 金额: $ 6.84万
• 依托单位: HARVARD MEDICAL SCHOOL
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-05-01 至 2012-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8358015
• 关键词: Antigens; BCG Vaccine; Calmette-Guerin Bacillus; Funding; Grant; Malignant Neoplasms; Mus; Mycobacterium bovis; National Center for Research Resources; New England; Primates; Principal Investigator; Recombinants; Research; Research Infrastructure; Resources; SIV; Source; United States National Institutes of Health; base; cost; immunogenic; immunogenicity; improved; mutant; nonhuman primate; pathogen; vaccine candidate; vector; vector vaccine

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. As Mycobacterium bovis bacillus Calmette-Gu¿rin (BCG) is known to be safe and immunogenic, it is currently being explored as a vaccine vector to confer protection against various pathogens and cancer. But little has been done systematically to optimize their immunogenicity in nonhuman primates. We have generated a number of mutants of BCG vaccine vector that have improved immunogenicity in mice. These mutants have been constructed to express SIV antigens. In this study we are assessing the immunogenicity of four such mutants in nonhuman primates.

这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 而子项目的主要调查员可能是由其他来源提供的， 包括其他NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量， 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 由于已知牛分枝杆菌卡介苗（BCG）是安全和免疫原性的，目前正在探索将其作为疫苗载体，以提供针对各种病原体和癌症的保护。但很少有人系统地优化它们在非人灵长类动物中的免疫原性。 我们已经产生了许多BCG疫苗载体的突变体，这些突变体在小鼠中具有改善的免疫原性。 这些突变体已被构建以表达SIV抗原。 在这项研究中，我们正在评估四个这样的突变体在非人灵长类动物的免疫原性。